- Home
- CFLT vs LEGN Comparison
CFLT vs LEGN Comparison
Compare CFLT & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CFLT
- LEGN
- Stock Information
- Founded
- CFLT 2014
- LEGN 2014
- Country
- CFLT United States
- LEGN United States
- Employees
- CFLT N/A
- LEGN N/A
- Industry
- CFLT EDP Services
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- CFLT Technology
- LEGN Health Care
- Exchange
- CFLT Nasdaq
- LEGN Nasdaq
- Market Cap
- CFLT 5.9B
- LEGN 6.7B
- IPO Year
- CFLT 2021
- LEGN 2020
- Fundamental
- Price
- CFLT $19.26
- LEGN $34.25
- Analyst Decision
- CFLT Buy
- LEGN Strong Buy
- Analyst Count
- CFLT 30
- LEGN 12
- Target Price
- CFLT $29.13
- LEGN $73.36
- AVG Volume (30 Days)
- CFLT 7.6M
- LEGN 1.1M
- Earning Date
- CFLT 10-29-2025
- LEGN 11-11-2025
- Dividend Yield
- CFLT N/A
- LEGN N/A
- EPS Growth
- CFLT N/A
- LEGN N/A
- EPS
- CFLT N/A
- LEGN N/A
- Revenue
- CFLT $1,064,824,000.00
- LEGN $796,838,000.00
- Revenue This Year
- CFLT $21.83
- LEGN $70.75
- Revenue Next Year
- CFLT $16.44
- LEGN $52.47
- P/E Ratio
- CFLT N/A
- LEGN N/A
- Revenue Growth
- CFLT 23.02
- LEGN 74.75
- 52 Week Low
- CFLT $15.64
- LEGN $27.34
- 52 Week High
- CFLT $37.90
- LEGN $52.31
- Technical
- Relative Strength Index (RSI)
- CFLT 48.47
- LEGN 43.57
- Support Level
- CFLT $19.17
- LEGN $32.70
- Resistance Level
- CFLT $20.09
- LEGN $34.71
- Average True Range (ATR)
- CFLT 0.80
- LEGN 1.20
- MACD
- CFLT 0.20
- LEGN 0.00
- Stochastic Oscillator
- CFLT 47.99
- LEGN 41.08
About CFLT Confluent Inc.
Confluent Inc provides a data streaming platform that enables customers to connect their applications, systems, and data layers and can be deployed as a fully managed cloud-native software-as-a-service (SaaS) offering. Its products include Confluent Cloud, a self-managed software offering, Confluent Platform, a managed service offering where the raw data resides inside a customer's cloud environment, and WarpStream, among others. Confluent also offers professional services and education services. The company generates revenue from the sale of subscriptions and services. Geographically, it generates a majority of its revenue from its business in the United States and the rest from International markets.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.